MacroGenics Inc (MGNX)

1.94 +11.85%

MacroGenics Inc (MGNX) is currently trading at $1.94. This represents a gain of 11.85% from the previous session. With a market capitalization of $0.12B, MGNX is a key component of the Health Care sector. Investors looking to trade MGNX should compare margin rates and options platforms to optimize their portfolio management.

Broker Promotion
Get 15 Free Stocks on Moomoo → T&Cs Apply. Trade MGNX commission-free.
Trading Platform Comparison
Moomoo
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Good for small traders
IBKR
  • Min Deposit: $0
  • Commissions: $0–$0.005/share
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Professional-level tools
Ameritrade
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Strong research tools
Webull
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Easy mobile app
AI Market Sentiment

As of today, MacroGenics Inc (MGNX) shows a bullish trend. Analysts are watching the 1.99 level closely.

Fundamentals
Mkt Cap0.12B
P/E Ratio0.0000
Volume1,057,359
Others Watching (By Market Cap)
TARA
Protara Therape $5.86
+7.04% AVTX
Avalo Therapeut $16.70
+3.12% EOLS
Evolus Inc $4.49
+4.30% ABEO
Abeona Therapeu $5.30
-1.57% TOI
Oncology Instit $2.87
+11.05%
60-Day Technical Chart
Advanced Charting

Need more indicators for MGNX? Use the world's #1 platform.

Open MGNX on TradingView →
Charting Platforms
TradingView

Advanced charts & indicators, web & mobile

StockCharts

Technical analysis charts with overlays & indicators

BarCharts

Market data, charts, and technical signals

Finviz

Visual stock charts & heatmaps

Yahoo Finance Charts

Basic interactive charts with indicators

Side-by-Side: Stocks Near $2
Metric MGNX
+11.85% 		PLUG
+0.00% 		BTBT
+7.90% 		OCGN
+4.78%
Price $1.94 $1.91 $1.82 $1.86
Mkt Cap $0.12B $2.66B $0.58B $0.61B
- View → View → View →
Latest Headlines
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) Seeking Alpha • Feb 24, 2026 FDA halts new enrollment in cancer trial after severe side effects Stock Titan • Feb 23, 2026 MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial GlobeNewswire • Feb 23, 2026 MacroGenics Insider Ups Holding By 909% During Year simplywall.st • Dec 18, 2025 MacroGenics, Inc. (NASDAQ:MGNX) is largely controlled by institutional shareholders who own 71% of the company Yahoo Finance • Jul 11, 2025
● Gemini Agentic AI Analyst Insight for MGNX
Market Education
View All Articles →
External Research